New Heart Failure Biomarkers in Early Stage Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD-HF)

Pr. Semir Nouira

Status: Completed

Conditions: Heart Failure; Kidney Disease, Chronic

Study type: Observational

Funder types: Other

Identifiers

NCT03307707

CKD-MBD-HF

Details and patient eligibility

About

the objective of this study is to :

-Determinate wether the circulating levels of iFGF23 and klotho can be a predictor biomarker of HF in patients with CKD-MBD.

Full description

The disorders of mineral metabolism and bone disease are common complications in CKD patients and they are associated with increased morbidity and mortality.

Abnormalities of the vasculature are seen in early CKD, producing vascular stiffness contributing to left ventricular hypertrophy and its pathophysiology involves newly discovered hormones, such as the fibroblast Growth factor 23 (FGF23) and α- klotho.

The FGF receptor and its co-receptor klotho moderate these effects. FGF23 levels inflate early in in the advancement of CKD stage to attain levels in CKD stage 5D.

But we still have few knoweledges if these markers can have some drawbacks for predicting CVD in early stage CKD.

Enrollment: 111 patients

Sex: All

Ages: 18 to 90 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Early CKD stage
• Heart failure

Exclusion criteria

• Infections
• cancer
• corticoid therapy
• renal replacement therapy
• Advanced CKD stage

Trial design

111 participants in 2 patient groups

Heart Failure (HF)

Description:

subjects with a Left Ventricular Ejection Fraction (LVEF) \<50% or LVEF \>50% and E/e'\>10.

No Heart Failure (NHF)

Description:

subjects with LVEF\>50%